BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026

BridgeBio highlights global approvals and safety data for acoramidis, but omits commercial figures.

What the company is saying

BridgeBio Pharma is emphasizing the clinical and regulatory strength of acoramidis, positioning it as the only selective small molecule, orally administered, near-complete (≥90%) transthyretin stabilizer for ATTR-CM. The company highlights that acoramidis is approved under the names Attruby and BEYONTTRA by the FDA, EMA, and other major regulators, with all labels specifying near-complete TTR stabilization. The announcement is structured around upcoming presentations at the American Heart Association Scientific Sessions 2026, including two moderated posters, three additional posters, and one Abbott Laboratories-led, BridgeBio-supported poster. The language asserts acoramidis as the 'first-line treatment of choice' for ATTR-CM, though this is not substantiated with comparative or market data. Safety data are presented with specific adverse event rates and discontinuation statistics, and the majority of adverse reactions are described as mild and self-resolving. The tone is confident and promotional, focusing on regulatory breadth and clinical profile, while omitting any mention of commercial performance or market uptake.

What the data suggests

Acoramidis has achieved regulatory approval in the US, EU, Japan, Switzerland, UK, Brazil, and Australia, with all agencies recognizing its near-complete (≥90%) stabilization of transthyretin. The product is indicated for treating cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular death and hospitalizations. In clinical studies, diarrhea occurred in 11.6% of patients on Attruby versus 7.6% on placebo, and upper abdominal pain in 5.5% versus 1.4%, respectively. Most adverse reactions were mild and did not require discontinuation. Discontinuation rates due to adverse events were 9.3% for Attruby and 8.5% for placebo, indicating a similar safety profile. The announcement does not disclose any sales, revenue, or market penetration figures, nor does it provide comparative efficacy data or head-to-head results against other therapies. The clinical and regulatory data are specific and complete, but the absence of commercial metrics prevents assessment of business impact or market adoption.

Analysis

The announcement is generally positive in tone, highlighting the presentation of new clinical data and reiterating the regulatory approvals for acoramidis (Attruby®/BEYONTTRA®) across multiple major markets. Most claims are realised and supported by specific regulatory and safety data, including adverse event rates and discontinuation statistics. The only forward-looking or potentially inflated claim is that the data 'further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice,' which is not substantiated by comparative or market share data in the release. There is no mention of new capital outlays, and the benefits of the product are already being realised, as evidenced by global approvals and clinical use. However, the absence of any commercial, sales, or financial metrics means investors cannot assess the business impact or uptake, limiting the signal to weak_positive. The language around 'first-line treatment of choice' and 'differentiated clinical profile' is somewhat promotional given the lack of comparative evidence in the disclosure.

Risk flags

• ●The absence of commercial, sales, or market uptake data creates uncertainty about the real-world business impact of acoramidis, despite broad regulatory approvals. Without these figures, investors cannot assess revenue growth, competitive positioning, or market adoption.
• ●The claim that acoramidis is the 'first-line treatment of choice' is not substantiated by comparative data, market share, or prescriber preference statistics in the announcement. This introduces a risk of overstatement and may not reflect actual clinical practice or guideline status.
• ●While adverse event rates and discontinuation statistics are disclosed, the higher rates of diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) compared to placebo could impact patient experience or adherence, though most reactions were mild and resolved without discontinuation.

Bottom line

BridgeBio is reinforcing the clinical and regulatory credentials of acoramidis, now approved in the US, EU, Japan, and other major markets, and providing detailed safety data that show a manageable adverse event profile. The announcement is timed around imminent scientific presentations but does not provide any commercial, sales, or revenue figures, leaving investors without insight into market uptake or financial performance. The company's claim that acoramidis is the 'first-line treatment of choice' is not backed by comparative or market data in this release. For investors, the main takeaway is that acoramidis is globally approved and has a defined safety profile, but the commercial trajectory remains unquantified. To change this assessment, BridgeBio would need to disclose sales, revenue, or market share data. The most actionable fact is the breadth of regulatory approvals and the imminent presentation of new clinical data.

Announcement summary

(NASDAQ:BBIO) BridgeBio Pharma, Inc. announced that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), as well as one BridgeBio-supported poster presentation led by Abbott Laboratories, will be presented at the American Heart Association (AHA) Scientific Sessions 2026, held in Chicago, Illinois from November 6-9, 2026. The company states that the data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is described as the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. Acoramidis is approved as Attruby® by the U.S. FDA and as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, the Brazilian Health Regulatory Agency (ANVISA), and the Australian Therapeutic Goods Administration (TGA), with all labels specifying near-complete stabilization of TTR. The moderated posters include 'Bridging the Diagnostic Gap in Transthyretin Cardiac Amyloidosis (ATTR-CM): Enhancing ATTR-CM Detection at the Time of Heart Failure Diagnosis in Women Through Sex-Specific ATTR Models (SS-ATTR-CMs)' presented by Hyewon Jeong, M.D., M.S., Massachusetts Institute of Technology, U.S., on Monday, November 9 at 9:50 am CT, and 'Artificial Intelligence for the Screening of ATTR Cardiomyopathy in the U.S.: A Multicenter Analysis from the TRACE-AI Network' presented by Bruno Batinica, MBChB, Yale School of Medicine, U.S., on Monday, November 9 at 11:20 am CT. The posters include 'Effects of Acoramidis on Heart Failure Events in Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM' presented by Mazen Hanna, M.D., Cleveland Clinic, U.S.; 'Risk of Multiple Cardiovascular-Related Hospitalizations and of All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: Findings from ATTRibute-CM Using Multistate Modeling' presented by Justin L. Grodin, M.D., UT Southwestern Medical Center, U.S.; and 'Recovery After Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights from an N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Analysis of the ATTRibute-CM Study' presented by Prem Soman, M.D., University of Pittsburgh Medical Center, U.S., all on Sunday, November 8 at 3:15 pm CT. The Abbott Laboratories-led, BridgeBio-supported poster 'Detection of Tetrameric Transthyretin by ARCHITECT c and Alinity c Assays' will be presented by Lici A. Schurig Briccio, Ph.D., Abbott Laboratories, U.S., on Monday, November 9 at 9:36 am CT. Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. Adverse reactions reported in patients treated with Attruby versus placebo include diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%), with most reactions being mild and resolving without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby and placebo (9.3% and 8.5%, respectively).

Disagree with this article?